
About Omega Therapeutics
Omega Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2016 by David Berry. Platform for human genome study is provided for precision medicine. Omega Therapeutics has raised $211 million across 3 funding rounds from investors including Fidelity Investments, Mirae Asset and BlackRock. The company has 93 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is OMEGA THERAPEUTICS, INC. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Omega Therapeutics was founded in 2016 and is based in Cambridge, United States. A proprietary platform known as GenomStats is employed to regulate genomic expression without modifying nucleic acid sequences. Focus is placed on precision medicine applications for rare genetic diseases, immunology, inflammation, metabolic disorders, and oncology. Operations center on advancing therapeutic solutions in the biotechnology sector.
- Headquarters Cambridge, United States
- Employees 93
- Founders David Berry
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website omegatherapeutics.com
- Social LinkedIn X
- Legal Name Omega Therapeutics, Inc.
- Annual Revenue$3.09 M (USD)49as on Dec 31, 2023
- Net Profit-$97.43 M (USD)5as on Dec 31, 2023
- EBITDA-$100.26 M (USD)2as on Dec 31, 2023
- Total Equity Funding$211M (USD)
in 3 rounds
- Latest Funding Round$126M (USD), Series C
Mar 2021
- InvestorsFidelity Investments
& 7 more
- Employee Count93
Funding Insights of Omega Therapeutics
Omega Therapeutics has successfully raised a total of $211M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $126 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $211M
- Total Rounds 3
- Last Round Series C β $126M
- Investors Count 8
All 3 funding rounds of Omega Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $126M | Series C | β | Invus, Logos | β |
| Jul 2020 | $85M | Series B | β | Flagship Pioneering | |
| Jun 2016 | Series A | β | β | β |
8 investors in total: 8 institutional.
Investors in Omega Therapeutics
Omega Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Manages alternative investments through equity, systematic, macro, and private strategies worldwide. | 2014 | point72.com | Stamford, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States | |
Mirae Asset Financial Group is engaged in global investment and financial services. | 1997 | miraeasset.com | Seoul, South Korea |
Investor details for Omega Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Omega Therapeutics
10 people are tracked at Omega Therapeutics (3 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 93.
| Name | Role | Group |
|---|---|---|
David Berry | Co-Founder | Leadership |
Benjamin Frempah | Director, Business Development | Leadership |
Justin Chen | Director | Leadership |
Rainer Boehm | Director | Board & advisors |
Rick Young | Director | Board & advisors |
Noubar Afeyan | Chairman & Founder | Board & advisors |
John Mendlein | Director | Board & advisors |
Elliott M. Levy | Director | Board & advisors |
Paul Aborn | Senior Manager, Accounting Operations | Team |
Daniel Costa | Sr. Scientist, Formulation And Drug Delivery | Team |
Complete people profiles for Omega Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Omega Therapeutics
4 dated milestones of Omega Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Omega Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $126.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Omega Therapeutics
Omega Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Omega Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Omega Therapeutics
Websites that share an audience with Omega Therapeutics (omegatherapeutics.com).
Websites whose visitors overlap most with Omega Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pharmavoice.com | pharmavoice.com | 100% | #720,985 | β | |
| flagshippioneering.com | 95% | 73.9K | #540,577 | View details | |
| fiercebiotech.com | 76% | 858.3K | #81,022 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Omega Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Omega Therapeutics
Complete news archive for Omega Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omega Therapeutics
Omega Therapeutics was founded in 2016.
Omega Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Omega Therapeutics is a funded company, having raised a total of $211M across 3 funding rounds to date.
Omega Therapeutics has 93 employees.
Annual revenue of Omega Therapeutics is $3.09M as on Dec 31, 2023.
Omega Therapeutics was founded in 2016 and is based in Cambridge, United States. A proprietary platform known as GenomStats is employed to regulate genomic expression without modifying nucleic acid sequences. Focus is placed on precision medicine applications for rare genetic diseases, immunology, inflammation, metabolic disorders, and oncology. Operations center on advancing therapeutic solutions in the biotechnology sector.
Omega Therapeutics's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.
Omega Therapeutics has 8 investors. Key investors include Fidelity Investments, Mirae Asset, BlackRock, TD Securities, and Flagship Pioneering.
Omega Therapeutics operates through Omega Therapeutics, Inc..
